Fluorescent PhthalocyanineâGraphene Conjugate ... - ACS Publications

Subscriber access provided by Kaohsiung Medical University

Article

Fluorescent Phthalocyanine-Graphene Conjugate with Enhanced NIR Absorbance for Imaging and Multi-Modality Therapy Jiabao Pan, Yang Yang, Wenjuan Fang, Wei Liu, Kai Le, Dongmei Xu, and Xiangzhi Li ACS Appl. Nano Mater., Just Accepted Manuscript • DOI: 10.1021/acsanm.8b00449 • Publication Date (Web): 15 May 2018 Downloaded from http://pubs.acs.org on May 16, 2018

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 35 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

ACS Applied Nano Materials

Fluorescent

Phthalocyanine-Graphene

Conjugate

with Enhanced NIR Absorbance for Imaging and Multi-Modality Therapy Jiabao Pan, †,‡ Yang Yang, #, ‡ Wenjuan Fang, † Wei Liu,*,† Kai Le, † Dongmei Xu, † and Xiangzhi Li*,# †

State Key Laboratory of Crystal Materials, Shandong University, Jinan 250100, P. R. China.

#

School of Medicine, Shandong University, Jinan 250012, P.R. China.

KEYWORDS: Graphene Oxide, Phthalocyanine, Photodynamic Therapy, Photothermal Therapy, Fluorescence.

ACS Paragon Plus Environment

1

ACS Applied Nano Materials 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 2 of 35

ABSTRACT

There has been increasing interest in design theranostic agents for combining diagnosis and different treatment modalities, especially for development physiological stable materials to avoid instability and dissociation in biological environment. Herein, a covalently connected silicon phthalocyanine (SiPc) and graphene oxide (GO) conjugate SiPc-GO is designed and synthesized via conjugation reaction to render stability. This novel highly water-soluble material displays intrinsically fluorescence and synchronous photothermal-photodynamic therapy (PTT/PDT) effect, along with 3-fold higher near-infrared (NIR) absorbance comparing to pristine GO. In vitro cell studies show that SiPc-GO could cause intracellular fluorescence, photothermal effect and reactive oxygen species (ROS) generation synchronously, and effective photoablation of cancer cells could be triggered by both 671 nm and 808 nm lasers via synergistic PTT/PDT or NIR photothermal effects, respectively. In vivo systemic administration in MCF-7 xenograft mice shows that SiPc-GO could effectively accumulate in the tumor regions and induce the inhibition of tumor growth violently after laser irradiation. This work establish SiPc-GO as a multimodality nano-sized photomedicine for cancer imaging, synergistic PTT/PDT and NIR photothermal therapy.


2

Page 3 of 35 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


1.

INTRODUCTION In present, surgery, chemotherapy and radiotherapy are still the mainstream of cancer

therapeutic modalities. However, these approaches have many limitations such as invasive, toxic side effects, poor tumor-selectivity and limited efficacy. In contrast to these conventional methods, photodynamic therapy (PDT) has attracted increasingly interest in cancer treatment due to its noninvasive, reduced side effects and improved tumor targeting nature.1,2 Unlike ionizing radiation, this “friendly” therapy enables patients to be treated repetitively without dosage limit and harmful side effect.3 In PDT, singlet oxygen (1O2) is considered to be the main reactive oxygen species (ROS) produced upon triggering photosensitizer (PS) by light and then transferring the photon energy to surrounding oxygen molecules, which induces cellular and tissue damage.1,4 Therefore, photosensitizer, molecular oxygen and light are identified as the three principal factors in PDT. 5,6 Over the last decades, various classes of PS have been developed to improve their photophysical, photochemical and PDT efficacy.7–10

Among these PSs, phthalocyanine (Pc) is a kind of

promising PS because of its high singlet oxygen generation, and intense absorption in red and NIR region that is recognized as optimal therapeutic window.11 In addition, silicon phthalocyanine (SiPc) with two axial ligands on the opposite sides of the macrocycle is considered to be one of the most hopeful PS for PDT, owing to its better photoactivity and biocompatibility.12 However, a typical feature of tumors is hypoxia, which would tremendously suppresses the efficiency of PDT, especially when oxygen is gradually exhausted as the treatment progresses.

13,14

Hence,

integrating PDT with other therapies to improve treatment efficacy is receiving much more attention. Photothermal therapy (PTT) is another type of phototherapy, which involves cell damage by heat generated from PTT agent via conversion of light absorption.15,16 So far, gold nanoparticles17,


3


Page 4 of 35

self-assembled nanostructured dyes18 and carbon nanomaterials19 have been identified as promising photothermal agents. Carbon nanomaterials, including fullerenes, carbon nanohorns20, carbon nanotubes,

21,22

and graphene,

23–25

have attracted intensely attention as PTT agents,

because of their good biocompatibility and photothermal conversion efficiency.

26,27

Due to its

abundant, low cost and convenient preparation from graphite, graphene has the advantages as PTT agent comparing to other carbon-based nanomaterials.28,29 In particular, graphene oxide (GO), the water-soluble derivative of graphene, has attracted much more attention due to its water-solubility and plentiful surface functional groups (carboxylic, epoxide and hydroxyl groups), enabling it with desirable physicochemical and biological properties.30–32 Recently, combined use of PDT and PTT for cancer treatment is receiving more and more interest due to the enormous enhancement of therapeutic efficacy. For examples, Liang et al. developed SWNHs−TSCuPc nanohybrid for both PTT and PDT;33 Mao et al. reported a type of GO modified with Ru(II)−polyethylene glycol complex for combining of PDT and PTT therapy.34 However, so far these dual-modality agents prepared from PS and carbon nanomaterials were all fabricated via π-π stacking interaction or electrostatic attraction and van der Waals interaction,35– 38

which are generally nonfluorescent and unstable/dissociated in physiological environment,

resulting in reduced therapeutic efficiency and enhanced side effects. In the present work, a covalently connected silicon phthalocyanine (SiPc) and graphene oxide (GO) conjugate SiPc-GO was designed and synthesized. To the best of our knowledge, this is the first covalently bonded hybrid system between GO and Pc for integrating PDT/PTT, along with fluorescence imaging properties. This novel nanocomposite displays intrinsically synchronous fluorescence, photothermal and photodynamic properties upon exposure to red light, which enable SiPc-GO to be an applicable theranostic agent for fluorescence imaging and combined noninvasive


4

Page 5 of 35 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


photodynamic and photothermal therapy. Meanwhile, its highly enhanced absorption in NIR region (>800 nm) enables SiPc-GO to treat more deep-seated or large solid tumors using NIR laser-driven photothermal therapy. The biological evaluations both in vitro and in vivo indicate synergetic anticancer efficacy of PDT and PTT along with good fluorescence emitting could be achieved via laser irradiation of SiPc-GO, showing this as-prepared SiPc-GO is an efficient and biocompatible multi-modality anticancer agent for fluorescence imaging, synergistic photodynamic-photothermal therapy and also NIR photothermal therapy. Scheme 1. Schematic illustration of the formation of SiPc-GO.


5


2.

Page 6 of 35

MATERIALS AND EXPERIMENTS 2.1． Chemicals and Materials. Graphene oxide powder (50-100 nm) was purchased from

Suzhou TANFENG graphene Tech Co., Ltd. Silicon phthalocyanine dichloride (SiPcCl2), 2-(2Aminoethoxy) ethanol, 1,3-diphenylisobenzofuran (DPBF), 1-(3-dimethylaminopropyl)-3ethylcarbodiimide

hydrochloride

(EDC•HCl),

N-hydroxysuccinimide

(NHS),

N,

N-

diisopropylethylamine (DIPEA) and polyoxyethylene castor oil (Cremophor EL, CEL) were purchased from Sigma-Aldrich. N, N-dimethylformamide (DMF) was distilled from barium oxide (BaO) under reduced pressure. All other reagents are in the purity of analytical grade and were used without further purification. 2.2. Synthesis of SiPc-NH2. Silicon phthalocyanine dichloride (SiPcCl2) (0.33 mmol), 2-(2Aminoethoxy) ethanol (2.64 mmol), K2CO3 (2.64 mmol) and pyridine (2 mL) were dissolved in 30 mL toluene. The reaction mixture was heated and refluxed at 130 ° C for 12 h under nitrogen atmosphere. After evaporation the volatiles, the residue was dissolved in chloroform (100 mL) and filtered. The filtrate was washed three times with deionized water and then concentrated under reduced pressure. The crud product was recrystallized from chloroform / n-hexane to give SiPcNH2 as a green solid (56.2%). 1H NMR (CD3OD, 300 MHz): δ -1.87 (4H, t, J = 3.4 Hz, CH2), 0.54 (4H, t, J =3.6 Hz, CH2), 1.72 (4H, t, J = 3.6 Hz, CH2), 1.81 (4H, t, J = 3.8 Hz, CH2), 8.43–8.46 (8H, m, Pc-H), 9.68–9.70 (8H, m, Pc-H).13C NMR (CD3OD, 75 MHz): δ 150.9, 137.1, 132.8, 124.8, 73.6, 73.4, 73.2, 62.2. Anal. Calcd. for C40H36N10O4Si: C 64.15, H 4.85, N 18.70%; found C 65.54, H 4.53, N 18.53%. MS (MALDI-TOF): m/z 749.004 (calcd. for [M+H]+ 749.269). 2.3. Synthesis of SiPc-GO. Graphene oxide (7 mg) was dispersed in DMF to a concentration of 0.5 mg/mL under sonication. Then EDC (0.4 mM), NHS (0.4 mM), DIPEA (3 mM) and SiPc-


6

Page 7 of 35 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


NH2 (74.9 mg, 0.1 mM) were added and the mixture was stirred for 3 days at room temperature under a nitrogen atmosphere. The mixture was dialyzed (molecular weight cut-off: 3500) in DMF repetitively for 3 days until the dialysate became colorless, and followed by dialysis using deionized water for 2 days. Then the final product was freeze-dried to give the conjugate of SiPcGO (20.6 mg), which was stored below 4℃ for further use (mass fraction of SiPc in SiPc-GO was calculated at ~ 66%, GO at ~34%). 2.4. Characterizations and Instruments. Ultraviolet-visible (UV-Vis) spectra were measured on a PerkinElmer Lambda-35 UV-Vis spectrometer and the samples were dispersed in H2O or DMF. The Raman spectra were recorded on a Horbin PHS-3C Raman spectrometers. Steady-state fluorescence spectra were obtained on a Hitachi F-2700 spectrofluorimeter equipped with a 450 W Xe lamp. FT-IR spectra were acquired on a Nicolet NEXUS 670 Fourier transformation infrared (FTIR) spectrometer. Atomic force microscopy (AFM) images were carried out on Dimension Icon (Veeco Instruments Inc) and by non-contact optical microscope (VHX1000C, Keyence). Xray-photoelectron (XPS) were investigated on a K-Alpha X-ray Photoelectron Spectrometer System (ESCALAB 250, Thermo, USA), and C1s (284.6 eV) was used to calibrate the peak positions for elemental analysis. The MTT assay was performed on a Bio-TEK ELX 800 microplate reader. 2.5. Singlet Oxygen Determination. 1, 3-diphenylisobenzofuran (DPBF) was used as a scavenger of the singlet oxygen (1O2). The DMF solution containing DPBF (4 mM) and SiPc-GO solution (20 µg • mL-1) was irradiated by red light (λ > 610 nm, 0.2 mW/cm2). The absorbance of DPBF at 415 nm was recorded every 5 seconds along with the irradiation.


7


Page 8 of 35

2.6. Photothermal Effect Measurement. SiPc-GO was dissolved in H2O with sonication to a final concentration of 20 µg • mL-1, and equivalent amount of GO (6.8 µg • mL-1) and SiPc-NH2 (13.2 µg • mL-1) were diluted correspondingly. Then 1 mL of each solution was placed in a cuvette and irradiated by a 671 /808 nm Laser for 5 min. The temperature change was recorded every 30 seconds using an infrared thermal imager (FLUKE Ti10, USA). 2.7. Cell Lines and Culture. Human breast cancer cell (MCF-7) and human cervical cancer cell (Hela) were used for biological evaluation. The cells were incubated in DMEM medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin (100 units • mL-1, streptomycin 100 µg • mL-1, respectively) at 37°C under 5% CO2. 2.8. Intracellular Fluorescence Imaging. Cells were seeded on a 6-well plate and cultured overnight at 37℃ under 5% CO2. Then cells were incubated with SiPc-GO in medium (10 µg • mL-1, 1.0 mL) for 24 h. After incubation, the cells were rinsed with PBS for three times and the fluorescence signals from the red channel were captured immediately with an Olympus FV 1200 confocal microscope. The control group was incubated with only medium and acquired under the same conditions. 2.9. Detection of Intracellular ROS.

The chloromethyl derivative of 2’, 7’-

dichlorodihydrofluorescein diacetate (CM-H2DCFDA) was used as an indicator for the detection of intracellular ROS. Cells were seeded on coverslips and cultured overnight at 37℃ under 5% CO2. Thereafter, the cells were cultured with SiPc-GO (10 µg • mL-1) in DMEM for 24 h. The control group was cultured in pure DMEM for 24 h. All cells were rinsed with PBS after incubation, then 100 µL of CM-H2DCFDA (10 µM) in PBS were added and cultured for another 15 min at 37℃ under 5% CO2. An LED array (λ≈ 660 nm, energy destiny: 0.2 mW/cm2) was used


8

Page 9 of 35 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


to irradiate the cells for 5 min afterwards. The fluorescence images were captured immediately after rinsed by PBS using an Olympus FV 1200 confocal microscope. 2.10. In Vitro Anticancer Efficacy. Cells were placed in 96-well plates (1×104 per well) and cultured overnight at 37 ℃ with 5% CO2. The cells were then incubated with different concentrations of SiPc-GO for 24 h. After incubation, the cells were rinsed with PBS twice and 100 µL of culture medium was added to each well before being illuminated. Then irradiation groups were exposed to 671 nm (2.5 W/ cm2) or 808 nm (12.5 W/ cm2) laser for 5 min, and cell viability was assessed 24 h after irradiation using MTT assay. Dark groups were acquired under the same conditions without irradiation; the control group was cultured with pure medium. 2.11. In Vivo Therapeutic Efficacy. All experiments using mice described herein were approved by the Animal Care and Utilization Committee of Shandong University and performed in accordance with applicable guidelines and regulations. NOD-SCID IL-2 receptor gamma null (NSG) female nude mice of 4-5 weeks old bearing MCF-7 cancer xenografts in both flanks (tumor size ca. 100 mm3) were randomized into two groups (n = 3) for control and evaluation of phototoxicity. SiPc-GO (3.8 mg/kg) in PBS was injected via the tail vein; control group was injected with PBS instead. At 24 h post injection, the mice were irradiated with a 671nm laser (2.5 W/cm2, 5 min) and thermal imaging was recorded every 1 min with an infrared thermal imager along with irradiation time. After irradiation (day 0), the tumor size was measured every 3 days with a caliper and tumor volume was calculated according to the following equation (1)39: tumor volume = (tumor length) × (tumor width)2/2

(1)

relative tumor volume calculated as V/V0, where V0 is the initial tumor volume on day 0.


9


3.

Page 10 of 35

RESULTS AND DISCUSSION 3.1． Synthesis and Characterization of SiPc-GO. In modern oncology, there has been

increasing interest in creating therapeutic agents for combining different treatment modalities to reinforce therapeutic effect. Among them, hybrid materials constructed by phthalocyanine and graphene have attracted remarkable attention due to their enormous potential for integrating PTT and PDT into a single system for cancer therapy. To improve their biological stability, herein, a covalently connected phthalocyanine and graphene oxide conjugate SiPc-GO was designed and synthesized.

First, a novel axial –NH2 terminated silicon phthalocyanine SiPc-NH2 was

synthesized via modification of SiPcCl2 with 2-(2-aminoethoxy) ethanol. Subsequent SiPc-GO was constructed via reactions between excess SiPc-NH2 and GO by the standard EDC/NHS conjugation procedure (scheme 1). The final product was purified by dialysis (molecular weight cut-off: 3500) in DMF and H2O successively to remove conjugation reagent (EDC/NHS) and excess of SiPc-NH2. The mass fraction of SiPc-NH2 in SiPc-GO was calculated at ~ 66%, showing SiPc-GO possesses a high Pc loading efficiency. Thus, this conjugation method is a very promising approach for integrating Pc and GO. The morphology of GO and as-prepared SiPc-GO were compared by AFM. As shown in Figure 1, the lateral dimension of GO ranges from 50 to 60 nm with a thickness, measured from the height profile of the AFM images, at ca. 9 nm. Whereas, the mean size for SiPc-GO averages 20~30 nm in diameter with a mean thickness at 4 nm, revealing the grafting of SiPc-NH2 onto GO breaks the GO sheets into much smaller pieces.


10

Page 11 of 35 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Figure 1. AFM imagines of GO (a, b) and SiPc-GO (c, d) and the height profile of GO (e) and SiPc-GO (f).


11


Page 12 of 35

Figure 2. (a)FT-IR spectra of SiPc-GO, GO and SiPc-NH2; (b) UV/Vis absorption curves and (c) Fluorescent spectra of SiPc-GO (20 µg • mL-1), GO (6.8 µg • mL-1) and SiPc-NH2 (13.2 µg • mL1

) in DMF; (d) Raman spectra and (e) XPS spectra of SiPc-GO, GO and SiPc-NH2.


12

Page 13 of 35 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


The Fourier transform infrared (FT-IR) spectra were used to trace the covalent bond formation in SiPc-GO. As shown in FT-IR spectrum of SiPc-GO (Figure 2a), apart from the main characteristic absorption bands from SiPc-NH2 and GO, the C=O absorption band at 1728 cm-1 (νC=O) attributed to the carboxylic acid groups from GO disappeared, followed by the appearance of a new band at 1663 cm-1 attributed to νC=O(NH) absorption in SiPc-GO, indicating the successful synthesis of SiPc-GO with amide linkage between SiPc and GO. The fluorescence and UV-vis spectra of GO, SiPc-NH2 and SiPc-GO, with equivalent concentrations of GO and SiPc-NH2, were performed in DMF. As shown in Figure 2b, the absorption curve of SiPc-GO exhibits the characteristic Soret- (λmax ~ 350 nm) and Q-band (λmax ~ 660 nm)40 peaks of SiPc-NH2 superimposing with the absorption of GO, suggesting the existence of both components of GO and silicon phthalocyanine. Compared to SiPc-NH2, a red-shift of B-band is observed for SiPc-GO. In addition, SiPc-GO exhibits stronger absorption in the NIR range with a ~ 3 fold increase at wavelength longer than 800 nm compared to that of GO, resulting in effective photothermal heating of SiPc-GO in NIR region. With the same concentrations of SiPc, relative lower fluorescence intensity is observed for SiPc-GO comparing to that of free SiPc-NH2 upon excitation at 610 nm, indicating a slightly intracellular energy loss occurs within SiPc-GO. In contrast, GO shows no fluorescence emission under the same conditions (Fig. 2c). Overall, the satisfactory fluorescence emission properties of SiPc-GO enable it to be a potential fluorescent imaging probe for cancers.


13


Page 14 of 35

Figure 3. High-resolution spectra of C1s XPS of GO (a) and SiPc-GO (b); N1s XPS spectra of SiPc-NH2 (c) and SiPc-GO (d) The formation of SiPc-GO was further characterized by Raman spectrum and X-rayphotoelectron spectroscopy (XPS). Figure 2d shows the Raman spectra of pristine GO, free SiPcNH2 and SiPc-GO. The spectrum of SiPc-GO exhibits all the main typical bands for SiPc-NH2 along with the superimposing with two additional bands at ~1337 cm-1 and ~1605 cm-1, which are corresponding to the D- and G-band of GO, 33 respectively, confirming the existence of both components of SiPc-NH2 and GO. Moreover, the covalent attachment of SiPc-NH2 onto the GO was further evidenced by photoelectron information from XPS. As shown in Figure 2e, only two


14

Page 15 of 35 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


main characteristic peaks corresponding to the C 1s and O 1s species can be observed for GO. In contrast, the XPS spectrum of SiPc-GO shows the photoelectrons collected from Si 2p, C 1s, N 1s and O1s, which come from both silicon phthalocyanine and GO. The N1s core-level spectrum of SiPc-NH2 can be curve-fitted into three peak components with binding energies 399.05 eV, 400.60 eV and 402.30 eV, which are attributed to nitrogen functionalities in C=N, C-N and N-H, respectively (Fig. 3c). After grafting SiPc-NH2 onto GO, one additional peak at 403.03 eV appears attributing to the N1s species for amide bond (O=C-N). In addition, all the bind energy of C=N (398.30 eV), C-N (399.60) and N-H (400.69) decrease by 0.75 eV, 1.0 eV and 1.61 eV, respectively, compared with that of free SiPc-NH2 (Fig. 3d). Due to the binding energy is related to the electron density around the nucleus, these energy decrease indicate that an electron density shift should occurred from GO to SiPc. Unlike peripheral connected GO,41,42 herein, GO shows the electron-donating properties towards SiPc. We deem this electron-donating to be the result of the shielding effect of the macrocyclic diamagnetic ring-current of SiPc towards GO through axial ligands.12 This result can be also proved by the high resolution spectra of C 1s. The C 1s spectrum of GO can be fitted into four peaks, which contains C-C/C=C at 284.60 eV, C-O at 286.63 eV, C=O at 288.20 eV and O=C-O at 289.68 eV (Fig. 3a). For comparison, the C1s XPS spectrum of SiPc-GO contains two additional peaks at 285.92 eV and 290.53 eV (Fig. 3 b), attributing to the C-N/C=N species originating from the silicon phthalocyanine and newly formed O=C-N, along with the disappearance of the peak for O=C-O. Furthermore, the binding energy of C-O (287.08 eV) and C=O (288.85 eV) increase by 0.45 eV and 0.65 eV, respectively, comparing with that of pristine GO. Such a binding energy increase again shows the decrease of electron density in GO, owing to its electron-donating properties towards silicon phthalocyanine. Furthermore, the C1s binding energy of O=C-N in SiPc-GO is another positive proof for the electron donating properties


15


Page 16 of 35

of GO. Theoretically, the C 1s binding energy of O=C-N should be lower than that of O=C-O, however, the C 1s energy of O=C-N (290.53 eV) in SiPc-GO is 0.85 eV higher than that of O=CO (289.68 eV) in GO, which further confirms the electron-donating properties of GO. 3.2. Singlet oxygen (1O2) Generation

The singlet oxygen (1O2) generation capability of SiPc-

GO was evaluated by a steady-state method using 1, 3-diphenylisobenzofuran (DPBF) as the quenching agent. The absorbance intensity of DPBF at 415 nm would be decreased gradually along with the generation of 1O2 by coexisting SiPc-GO under a red light (λ > 610 nm, 0.2 mW/cm2). For comparison, the 1O2 generation efficiency of SiPc-GO was detected in both DMF and water (Fig. 4a, b). The DPBF consumption rates in DMF and H2O are compared in Figure 4c. Although SiPc-GO is more aggregated in H2O, it could still produces 1O2 efficiently.

The DPBF

consumption ratios in DMF and H2O are 49.8% and 40% within 50 seconds of irradiation, showing its satisfactory 1O2 generation efficiency both in DMF and water. It worth to mention, herein, Cremophor EL (0.1%, v/v) was added to reduce the aggregation and chain reaction of DPBF in water during the photo-oxidative process by 1O2 (Fig. S3). In addition, a homogeneous suspension in water could be obtained for SiPc-GO without sonication, however, clustering was found for GO under the same conditions (Fig. 4d). SiPc-GO also displayed excellent dispersity in physiological solutions of PBS and DMEM as shown by dynamic light scattering (DLS) analysis (Fig. 4e). The ξ potentials in PBS and pure H2O were measured to be -20.99 mV and -21.46, respectively (Fig. 4f). All these data show that SiPc-GO has good stabilities in physiological solutions.


16

Page 17 of 35 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Figure 4. UV/Vis absorption spectra for the determination of the 1O2 of SiPc-GO in (a) DMF and (b) H2O containing Cremophor EL (0.1%, v/v) irradiated by red light (λ > 610 nm 0.2 mW/cm2);


17


Page 18 of 35

(c) The relative absorbance of DPBF (A0 and A are the absorbance of DPBF at 415 nm before and after irradiation); (d) Photo images of GO and SiPc-GO dispersion in H2O without sonification.; (e) DLS analysis of SiPc-GO in physiological solutions; (f) The ξ potentials of SiPc-GO.

Figure 5. (a) Thermal images of SiPc-GO (20 µg • mL-1), GO (6.8 µg • mL-1), SiPc-NH2 (13.2 µg • mL-1) and deionized water under 808 nm laser (12.5 W/cm2) respectively. (b) The corresponding time-dependent photothermal curves of the samples. 3.3. Photothermal Properties of SiPc-GO. The photothermal responses of GO, SiPc-NH2 and SiPc-GO were recorded and compared by a thermal imager. We first used an 808 nm NIR laser (12.5 W/cm2) for irradiation to verify their photothermal efficacy in NIR region. The temperature of SiPc-GO readily increased over 50 ℃ within 5 min of irradiation (∆T~25 ℃ ), which is


18

Page 19 of 35 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


considered as the photoablation limit of living cells (Fig. 5). In contrast, the thermal signals of GO and SiPc-NH2 showed much smaller changes (∆T< 10℃) under the same conditions. As a control, no obvious change could be observed for pure water. The photothermal heating by a 671 nm laser followed the same order of SiPc-GO >> SiPc-NH2 > GO > H2O as that of 808 nm laser. As a result, it could be concluded that both SiPc and GO contribute to the photothermal effect of SiPc-GO. The photothermal conversion efficiency of SiPc-GO was measured and calculated to be 20.20% according to the published procedure (Figure S4).35

3.4. Intracellular Fluorescence. The intracellular fluorescence of SiPc-GO in Hela cancer cells was conducted by a confocal microscope to evaluate its cellular uptake and subcellular localization. As shown in Figure 6a, bright intracellular fluorescence images could be observed for SiPc-GO after incubation for 24 h at a concentration of 10 µg • mL-1, showing SiPc-GO could enter the cells and cause cellular fluorescence in cytoplasm. In contrast, no fluorescence could be detected for the control cells. 3.5. Intercellular ROS Generation. The intracellular generation of reactive oxygen species (ROS) was investigated in Hela cells using CM-H2DCFDA as the probe. CM-H2DCFDA is a cellpermeant indicator for ROS that turns into fluorescent by oxidation in the cells. After incubation with SiPc-GO for 24 h, the cells were then incubated with CM-H2DCFDA for another 15 min before illumination. Upon illumination by a 660 nm red light, it was found that the cells incubated with SiPc-GO could produce significant amount of ROS. However, the cells incubated without SiPc-GO could not generate ROS, indicating SiPc-GO is an efficient PDT photosensitizer inside cancer cells (Figure. 6b).


19


Page 20 of 35

Figure 6. (a) Confocal fluorescence images of HeLa cells after being incubated by SiPc-GO (10 µg • mL-1) and PBS for 24 h; (b) Confocal fluorescence images of HeLa cells stained by CM-


20

Page 21 of 35 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


H2DCFDA (10 µM) after being incubated by SiPc-GO (10 µg • mL-1) for 10 h and irradiated by LED light (λ> 660 nm, 0.2 mW/cm2) for 5 min.

Figure 7. (a) Hela cells treated with SiPc-GO at different concentrations and irradiated by different lasers (808 nm, 12.5 W/cm2; 671 nm, 2.5 W/cm2) for 5 min. (b) Comparison of SiPcGO (10 μg • mL-1), GO (3.4 μg • mL-1) and PBS in Hela cells by different lasers for 5 min; Dark cytotoxicity of SiPc-GO, SiPc-NH2 and GO against (c)Hela and (d) MCF-7 cells.


21


Page 22 of 35

3.6. In Vitro Anticancer Efficacy. For evaluation of in vitro therapeutic efficacy, we studied the anticancer effects of SiPc-GO in both Hela and MCF-7 cancer cells. Two sets of laser system with wavelengths of 808 nm or 671 nm were utilized to proof the synergistic effect of PDT and PTT. First, an 808 nm NIR laser was used for irradiation, of which the cell killing effect was assumed solely by the NIR photothermal heating since lights with wavelengths longer than 800 nm have insufficient energy to initiate a photodynamic reaction.6, 43 Cells were first incubated with different concentrations of SiPc-GO for 24 h. Then cell viabilities were monitored 24 h after the photothermal treatment by an 808 nm laser (12.5 W/cm2, 5 min) using MTT assay. Cells without samples were used as a control. The cell viabilities dropped to ∼70% and ∼45% for the cells incubated with SiPc-GO at concentrations of 10 µg • mL-1 and 20 µg • mL-1, respectively. For comparison, the viabilities for cells irradiated by a 671 nm laser (2.5 W/cm2, 5 min), of which the laser power was adjusted to cause comparable photothermal heating as that of the 808 nm laser, decreased significantly to 50% and 35%, respectively (Figure.7a). As aforementioned, both singlet oxygen and photothermal heating could be initiated for SiPc-GO by a red light. Hence, this significant phototoxicity increase revealed that a combined therapeutic effect of PDT/PTT was triggered by the 671 nm laser. Furthermore, the successively use of both 671 and 808 nm lasers gave even lower cell viabilities of ~30% and ~ 20% at SiPc-GO concentrations of 10 µg • mL-1 and 20 µg • mL-1, respectively, which further confirmed the good therapeutic efficacy of SiPc-GO. At the equivalent concentration of GO, remarkable enhanced cell killing effect could be observed for SiPc-GO comparing to that of GO when irradiated either by 671 nm or 808 nm lasers (Fig. 7b), which further evidenced the synergistic effect of PDT/PTT in red region and efficient hotothermal effect in NIR region.


22

Page 23 of 35 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


To give insight into the biocompatibility of SiPc-GO, the dark toxicity of SiPc-GO, SiPc-NH2 and GO were evaluated by the standard MTT assay. As shown in Figure 7 (c,d), the cell viabilities were >95% for SiPc-GO at the concentrations up to 20 µg • mL-1 after incubation for 24 h, indicating the satisfactory biocompatibility of SiPc-GO. The cell viability of GO was also >95% at the concentration of 6.8 µg • mL-1, and >90% at the concentration of 15 µg • mL-1. On the contrary, only 25% cell viability was left for free SiPc-NH2 at the equivalent concentration of 13.2 µg • mL-1. These results obviously manifest that the grafting of SiPc-NH2 onto GO could significantly reduce the cytotoxicity of SiPc-NH2. On the other hand, these cytotoxicity changes could further certify the successful conjugation between SiPc-NH2 and GO via covalent bond. 3.7. In Vivo Anticancer Efficacy. In vivo anticancer efficacy was investigated via intravenous injection of SiPc-GO (3.8 mg/kg) into NSG female mice bearing MCF-7 tumors. At 24 h post injection, the mice were irradiated with a 671nm laser (2.5 W/cm2, 5 min) and thermal imaging was recorded every 1 min with an infrared thermal imager along with irradiation time. The infrared thermal mapping images are show in Figure 8a. After irradiation for 5 min, the temperature of the tumor rapidly increased to 66.5℃ (∆T= 32.5 ℃), which caused irreversible destruction toward cancer cells. In contrast, the control group that was injected with PBS instead exhibited much lower temperature increase with a ∆T = 15.2℃, indicating that SiPc-GO accumulated in tumor region and played a crucial role in photothermal heating.


23


Page 24 of 35

Figure 8. (a) IR thermal images of MCF-7 tumor-bearing mice exposed to 671 nm laser (2.5 W/cm2); (b) Temperature change curves of mice along with irradiation time; (c) Representative photos of mice from each experimental group during the treatments. (d) Relative tumor volume curves of mice. Subsequently, tumor growth rates were monitored to verify the therapeutic efficacy of combined PTT and PDT. The tumor size was measured every 3 days with a caliper and tumor volume was


24

Page 25 of 35 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


calculated. As shown in Figure 8 (c, d), the tumor growth was violently inhibited in the SiPc-GO group. On the contrary, the tumor size of control group continuously increased without shrinkage of tumor volume. The comparison of tumor size between the control and SiPc-GO groups clearly demonstrated the excellent phototherapeutic effect of SiPc-GO. In addition, the mouse weights were also monitored to evaluate the toxicity of SiPc-GO in vivo. No obvious weight changes were observed for mice in either control or SiPc-GO groups, indicating that SiPc-GO had negligible toxicity in vivo. Overall, these results show that SiPc-GO is an effective anticancer agent with synergistic effect of PDT and PTT, along with satisfactory biocompatibility.

4.

CONCLUSIONS In summary, we developed a biocompatible nanosized photomedicine SiPc-GO via covalent

amide bond between GO and SiPc. SiPc-GO could exhibit intrinsically fluorescence and synergistic PDT/PTT properties in red region, along with efficient PTT efficacy in NIR region. In vitro cell studies showed that SiPc-GO could cause cellular fluorescence, intracellular temperature increase and reactive oxygen species (ROS) synchronously by lasers. Significant phototoxicity could be observed for SiPc-GO in Hela cancer cells due to the synergistic effect of PDT/PTT driven by a 671 nm laser. In addition, effective PTT result could also be triggered by a NIR 808 nm laser. In vivo anticancer efficacy in NSG female mice bearing MCF-7 tumors showed the tumor temperature rapidly increased to 66.5℃ (∆T= 32.5 ℃) within 5 min laser irradiation and the tumor growth was violently inhibited in the mice group injected with SiPc-GO. For comparison, the control group exhibited much lower temperature increase and negligible tumor growth inhibition. Our both in vitro and in vivo results show that SiPc-GO is an efficient and biocompatible multi-


25


Page 26 of 35

modality anticancer agent for fluorescence imaging, synergistic PDT/PTT therapy and NIR PTT therapy.

ASSOCIATED CONTENT Supporting Information.

1

H NMR, 13C NMR spectra of SiPc-NH2. Additional details on the

photothermal conversion efficiency of SiPc-NH2. Comparison of UV-vis absorption of DPBF in water with and without Cremophor EL (0.1%, v/v). AUTHOR INFORMATION Corresponding Author * E-mail: [email protected] Tel: (+86) 0531-88365606 (W. Liu) * E-mail: [email protected] (X. Li) Author Contributions These authors contributed equally to this work.

‡

Notes The authors declare no competing financial interest. ACKNOWLEDGMENT This work was supported by the grant from Natural Science Foundation of Shandong Province (ZR2016BM16); Science and Technology Development Plan Project of Shandong Province


26

Page 27 of 35 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


(2014GGX102004) and The Fundamental Research Funds of Shandong University (2015JC036). We thank Dr. Gang Lian for his beneficial discussion with GO.

REFERENCES (1)

Dolmans, D. E.; Fukumura, D.; Jain, R. K. Photodynamic Therapy for Cancer. Nat. Rev.

2003, 3, 380–387. (2)

Brown, S. B.; Brown, E. A.; Walker, I. The Present and Future Role of Photodynamic

Therapy in Cancer Treatment. Lancet Oncol. 2004, 5, 497–508. (3)

Dougherty, T. J.; Gomer, C. J.; Henderson, B. W.; Jori, G.; Kessel, D.; Korbelik, M.; Moan,

J.; Peng, Q. Photodynamic Therapy. J. Natl. Cancer Inst. 1998, 90, 889–905. (4)

Luan, L.; Fang, W.; Liu, W.; Tian, M.; Ni, Y.; Chen, X.; Yu, X. Phthalocyanine-cRGD

Conjugate: Synthesis, Photophysical Properties and in Vitro Biological Activity for Targeting Photodynamic Therapy. Org. Biomol. Chem. 2016, 2985–2992. (5)

Henderson, B. W.; Dougherty, T. J. How Does Photodynamic Therapy Work? Photochem.

Photobiol. 1992, 55, 145–157. (6)

Agostinis, P.; Berg, K.; Cengel, K. A; Foster, T. H.; Girotti, A. W.; Gollnick, S. O.; Hahn,

S. M.; Hamblin, M. R.; Juzeniene, A.; Kessel, D.; Korbelik, M.; Moan, J.; Mroz, P.; Nowis, D.; Piette, J.; Willson, B. C.; Golab, J. Photodynamic Therapy of Cancer : An Update. CA. Cancer J. Clin. 2011, 61, 250–281.


27


(7)

Page 28 of 35

Huang, P.; Xu, C.; Lin, J.; Wang, C.; Wang, X.; Zhang, C.; Zhou, X.; Guo, S.; Cui, D.

Folic Acid-Conjugated Graphene Oxide Loaded with Photosensitizers for Targeting Photodynamic Therapy. Theranostics 2011, 1, 240–250. (8)

Zhao, Z. X.; Huang, Y. Z.; Shi, S. G.; Tang, S. H.; Li, D. H.; Chen, X. L. Cancer Therapy

Improvement with Mesoporous Silica Nanoparticles Combining Photodynamic and Photothermal Therapy. Nanotechnology 2014, 25, 285701-285709. (9)

Li, Y.; Zheng, X.; Zhang, X.; Liu, S.; Pei, Q.; Zheng, M.; Xie, Z. Porphyrin-Based Carbon

Dots for Photodynamic Therapy of Hepatoma. Adv. Healthc. Mater. 2017, 6, 1–6. (10)

Rong, P.; Yang, K.; Srivastan, A.; Kiesewetter, D. O.; Yue, X.; Wang, F.; Nie, L.; Bhirde,

A.; Wang, Z.; Liu, Z.; Niu, G.; Wang, W.; Chen, X. Photosensitizer Loaded Nano-Graphene for Multimodality Imaging Guided Tumor Photodynamic Therapy. Theranostics 2014, 4, 229–239. (11)

Bonnett, R. Photosensitizers of the Porphyrin and Phthalocyanine Series for Photodynamic

Therapy. Chem. Soc. Rev. 1995, 24, 19–33. (12)

Luan, L.; Ding, L.; Shi, J.; Fang, W.; Ni, Y.; Liu, W. Effect of Axial Ligands on the

Molecular Configurations, Stability, Reactivity, and Photodynamic Activities of Silicon Phthalocyanines. Chem. - An Asian J. 2014, 9, 3491–3497. (13)

Cheng, L.; Wang, C.; Feng, L.; Yang, K.; Liu, Z.

Functional Nanomaterials for

Phototherapies of Cancer. Chem. Rev. 2014, 114, 10869-10939. (14)

Chen, G.; Roy, I.; Yang, C.; Prasad, P. N. Nanochemistry and Nanomedicine for

Nanoparticle-Based Diagnostics and Therapy. Chem. Rev. 2016, 116, 2826–2885.


28

Page 29 of 35 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


(15)

Camerin, M.; Rodgers, M. A. J.; Kenney, M. E.; Jori, G. Photothermal Sensitization:

Evidence for the Lack of Oxygen Effect on the Photosensitizing Activity. Photochem. Photobiol. Sci. 2005, 4, 251–253. (16)

Bucking, M.; Dickson, E. F. G.; Farahani, M.; Fischer, F.; Holmes, D.; Jori, G.; Kennedy,

J. C.; Kenney, M. E.; Peng, X.; Pottier, R. H.; Weagle, G. Quantification of the Selective Retention of Palladium Octabutoxynaphthalocyanine, a Potential Photothermal Drug, in Mouse Tissues. J. Photochem. Photobiol. B Biol. 2000, 58, 87–93. (17)

Jang, B.; Park, J.; Tung, C.; Kim, I.; Choi, Y. Gold Nanorod-Photosensitizer Complex for

Near-Infrared Fluorescence Imaging and Photodynamic/Photothermal Therapy In Vivo. ACS Nano. 2011, 5, 1086–1094. (18)

Li, X.; Kim, C.; Lee, S.; Lee, D.; Chung, H; Kim, G.; Heo, S.; Kim, C.; Hong, K.; Yoon,

J. Nanostructured Phthalocyanine Assemblies with Protein-Driven Switchable Photoactivities for Biophotonic Imaging and Therapy. J. Am. Chem. Soc. 2017, 139, 10880–10886. (19)

Georgakilas, V.; Tiwari, J. N.; Kemp, K. C.; Perman, J. A.; Bourlinos, A. B.; Kim, K. S.;

Zboril, R. Noncovalent Functionalization of Graphene and Graphene Oxide for Energy Materials, Biosensing, Catalytic, and Biomedical Applications. Chem. Rev. 2016, 116, 5464–5519. (20)

Yang, L.; Ran, X.; Cai, L.; Li, Y.; Zhao, H; Li, C. Calix[8]arene functionalized single-

walled carbon nanohorns for dual-signalling electrochemical sensing of aconitine based on competitive host-guest recognition. Biosens. Bioelectron 2016, 83, 347-352. (21)

Modugno, G.; Ménard-Moyon, C.; Prato, M.; Bianco, A. Carbon Nanomaterials Combined

with Metal Nanoparticles for Theranostic Applications. Br. J. Pharmacol. 2015, 172, 975–991.


29


(22)

Page 30 of 35

Ogbodu, R. O.; Ndhundhuma, I.; Karsten, A.; Nyokong, T. Photodynamic Therapy Effect

of Zinc Monoamino Phthalocyanine-Folic Acid Conjugate Adsorbed on Single Walled Carbon Nanotubes on Melanoma Cells. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2015, 137, 1120– 1125. (23)

Chen, Y.; Tan, C.; Zhang, H.; Wang, L. Two-Dimensional Graphene Analogues for

Biomedical Applications. Chem. Soc. Rev. 2015, 44, 2681–2701. (24)

Gao, S.; Zhang, L.; Wang, G.; Yang, K.; Chen, M.; Tian, R.; Ma, Q.; Zhu, L. Hybrid

graphene/Au Activatable Theranostic Agent for Multimodalities Imaging Guided Enhanced Photothermal Therapy. Biomaterials 2016, 79, 36–45. (25) Karousis, N.; Ortiz, J.; Ohkubo, K.; Hasobe, T.; Fukuzumi, S.; Sastre-Santos, A ́ .; Tagmatarchis, N. Zinc Phthalocyanine − Graphene Hybrid Material for Energy Conversion: Synthesis, Characterization, Photophysics, and Photoelectrochemical Cell Preparation. J. Phys. Chem. C. 2012, 116, 20564-20573. (26)

Tian, B.; Wang, C.; Zhang, S.; Feng, L.; Liu, Z. Photothermally Enhanced Photodynamic

Therapy Delivered by Nano-Graphene Oxide. ACS Nano 2011, 5, 7000–7009. (27)

Jiang, B.; Hu, L.; Wang, D.; Ji, S.; Shen, X.; Liang, H. Graphene Loading Water-Soluble

Phthalocyanine for Dual-Modality Photothermal/photodynamic Therapy via a One-Step Method. J. Mater. Chem. B 2014, 2, 7141–7148. (28)

Zhang, Y.; Nayak, T. R.; Hong, H.; Cai, W. Graphene: A Versatile Nanoplatform for

Biomedical Applications. Nanoscale 2012, 4, 3833-3842.


30

Page 31 of 35 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


(29)

Ma, Y.; Huang, J.; Song, S.; Chen, H.; Zhang, Z. Cancer-Targeted Nanotheranostics:

Recent Advances and Perspectives. Small 2016, 12, 4936–4954. (30)

Liu, Z.; Robinson, J. T.; Tabakman, S. M.; Yang, K.; Dai, H. Carbon Materials for Drug

Delivery & Cancer Therapy. Mater. Today 2011, 14, 316–323. (31)

Sahu, A.; Choi, W.; Lee, J. H.; Tae, G. Graphene Oxide Mediated Delivery of Methylene

Blue for Combined Photodynamic and Photothermal Therapy. Biomaterials 2013, 34, 6239–6248. (32)

Liu, Z.; Robinson, J. T.; Sun, X.; Dai, H. PEGylated Nano-Graphene Oxide for Delivery

of Water Insoluble Cancer Drugs (B). J. Am. Chem. Soc. 2008, 130, 10876–10877. (33)

Jiang, B.; Hu, L.; Shen, X.; Ji, S.; Shi, Z.; Liu, C.; Zhang, L.; Liang, H. One-Step

Preparation of a Water-Soluble Carbon Nanohorn / Phthalocyanine Hybrid for Dual-Modality Photothermal and Photodynamic Therapy. ACS Appl. Mater. Interfaces 2014, 6, 18008–180017. (34)

Zhang, D.; Zheng, Y.; Tan, C.; Sun, J.; Zhang, W.; Ji, L.; Mao, Z. Graphene Oxide

Decorated with Ru(II)-Polyethylene Glycol Complex for Lysosome-Targeted Imaging and Photodynamic/Photothermal Therapy. ACS Appl. Mater. Interfaces 2017, 9, 6761–6771. (35)

Du, L.; Qin, H.; Ma, T.; Zhang, T.; Xing, D. In Vivo Imaging-Guided

Photothermal/Photoacoustic

Synergistic

Therapy

with

Bioorthogonal

Metabolic

Glycoengineering-Activated Tumor Targeting Nanoparticles. ACS Nano 2017, 11, 8930–8943. (36)

Dong, H.; Zhao, Z.; Wen, H.; Li, Y.; Guo, F.; Shen, A.; Frank, P.; Lin, C.; Shi, D.

Poly(ethylene Glycol) Conjugated Nano-Graphene Oxide for Photodynamic Therapy. Sci. China Chem. 2010, 53, 2265–2271.


31


(37)

Page 32 of 35

Wu, C.; He, Q.; Zhu, A.; Li, D.; Xu, M.; Yang, H.; Liu, Y. Synergistic Anticancer Activity

of Photo-and Chemo-Responsive Nanoformulation Based on Polylysine Functionalized Graphene. ACS Appl. Mater. Interfaces 2014, 6, 21615–21623. (38)

Qin, X. C.; Guo, Z. Y.; Liu, Z. M.; Zhang, W.; Wan, M. M.; Yang, B. W. Folic Acid-

Conjugated Graphene Oxide for Cancer Targeted Chemo-Photothermal Therapy. J. Photochem. Photobiol. B 2013, 120, 156–162. (39)

Tao, Y.; Ju, E.; Ren, J.; Qu, X. Immunostimulatory Oligonucleotides-Loaded Cationic

Graphene Oxide with Photothermally Enhanced Immunogenicity for Photothermal/immune Cancer Therapy. Biomaterials 2014, 35, 9963–9971. (40)

Imahori, H.; Umeyama, T.; Ito, S. Large π-Aromatic Molecules as Potential Sensitizers for

Highly Efficient Dye-Sensitized Solar Cells. Acc. Chem. Res. 2009, 42, 1809–1818. (41)

Olgac, R.; Soganci, T.; Baygu, Y.; Gök, Y.; Ak, M. Zinc(II) Phthalocyanine Fused in

Peripheral

Positions

Octa-Substituted

with

Alkyl

Linked

Carbazole:

Synthesis,

Electropolymerization and Its Electro-Optic and Biosensor Applications. Biosens. Bioelectron. 2017, 98, 202–209. (42)

Wang, Z.; He, C.; Song, W.; Gao, Y.; Chen, Z.; Dong, Y.; Zhao, C.; Li, Z.; Wu, Y. The

Effect of Peripheral Substituents Attached to Phthalocyanines on the Third Order Nonlinear Optical Properties of Graphene oxide–zinc(II)phthalocyanine Hybrids. RSC Adv. 2015, 5, 94144– 94154.


32

Page 33 of 35 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


(43) Yang, C.; Guo, C.; Guo, W.; Zhao, X.; Liu, S.; Han, X. Multifunctional Bismuth Nanoparticles as Theranostic Agent for PA/CT Imaging and NIR Laser-Driven Photothermal Therapy. ACS Appl. Nano Mater. 2018, 1, 820-830.


33


Page 34 of 35

Table of Content


34

Page 35 of 35 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


252x109mm (150 x 150 DPI)


Fluorescent PhthalocyanineâGraphene Conjugate ... - ACS Publications

Recommend Documents

Fluorescent PhthalocyanineâGraphene Conjugate ... - ACS Publications